BI 836880 + ezabenlimab

BI 836880 + ezabenlimab is an investigational combination therapy for advanced solid tumors. It consists of two agents: - **BI 836880** is a humanized bispecific nanobody that targets and inhibits both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), thereby blocking key pathways involved in tumor angiogenesis and vascular remodeling. - **Ezabenlimab** (also known as BI 754091) is a monoclonal antibody that acts as an immune checkpoint inhibitor by targeting programmed death protein-1 (PD-1), enhancing the immune system's ability to recognize and attack cancer cells. The combination aims to provide synergistic antitumor effects by simultaneously inhibiting tumor blood vessel formation and reactivating anti-tumor immunity. Clinical trials have evaluated this regimen in various advanced solid tumors, including colorectal cancer, hepatocellular carcinoma, glioblastoma multiforme, non-small cell lung cancer, endometrial carcinoma, and others. The combination has shown manageable safety profiles with preliminary evidence of clinical activity[1][2][3][4][5].

Other names

ezabenlimab + BI 836880